Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Now NPPA to cut the...

    Now NPPA to cut the price of Condoms

    Written by savita thakur thakur Published On 2017-03-02T17:17:46+05:30  |  Updated On 12 Feb 2020 1:05 PM IST
    Now NPPA to cut the price of Condoms

    In a latest notification, the National Pharmaceutical Pricing Authority (NPPA) has presented its idea to re-fix the price of condoms as condoms have been part of the National List of Essential Medicines from 2003.


    Business Standard reports that The National Pharmaceutical Pricing Authority has decided to set a fix price for for basic utility condoms and the other for pleasure condoms. In a view to implement their idea, the authority has asked the manufactures to submit the details of the product along with "supporting documents like invoices to retailer and samples of August 2015".


    As per the NPPA price capping rule, condoms comes under the Schedule 1 of the Drug Price Control Order of 2012, after which NPPA could cap its price.


    Earlier, the NPPA's decision to cap the price of condom was challenged by companies at the high court level over the procedure. Reckitt Benckiser and JK Ansell challenged two NPPA orders and contended condoms were not drugs, but devices, and could not be included in the DPCO of 2013. Over the Reckitt Benckiser and JK pleam Delhi High court ruled the argument in favour of two pharma companies, Reckitt Benckiser and J K Ansell Ltd (JKAL), for their plea to remove the price ceiling for condom. The two companies had put forward their legal plea to contend that their products were 'devices' and not 'medicines' and thus would not fall under the DPCO and hence, no cap can be put on their prices.


    According to NPPA's order in November 5, 2013, initially capped condom prices at Rs 6.56 each and this was later increased to Rs 8.04 by its July 10, 2014, notification, reports



    Pointing towards the condom manufacturing companies and their profit margins in the market, NPPA has presented the data of these companies as, Skore Condoms, distributed by Chennai-based TTK Healthcare has a market share of around 10 per cent. Mankind Pharmais reported to have been the leader, with its Manforce brand having a market share of around 32 per cent. Moods condoms hace 16-17 per cent, Durex has two to three per cent and Kohinoor seven to eight per cent.


    Source : With inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok